PharmaTelevision - Janssen Pharmaceuticals LLC: Rob Wills talks about changes in alliance management practices over the past few years

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Janssen Pharmaceuticals LLC: Rob Wills talks about changes in alliance management practices over the past few years

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Rob Wills, Vice President Alliance Management of Janssen Pharmaceuticals LLC.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Changes in biotech funding

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington DC. On this show, I have Rob Wills, who is Vice President of Alliance Management at Janssen Pharmaceuticals, which is part of the family of Johnson & Johnson companies, welcome.

Rob Wills:

Thank you.

Fintan Walton:

Rob, first of all just tell us there has been an sort of harmonization of the name within the Johnson & Johnson companies we've known of centre core Ortho-McNeil and so forth tell us first of all what's happened?

Rob Wills:

So the trend here Fintan is to have like a consolidation of all the companies in the pharmaceutical group into one common identity, we think it's important for payers, for customers, for people that we interact with everyday, we still have a decentralized philosophy and that was the hallmark of our business model, but it was often very confusing with all the different company names so we decided to just you know put it all under a common identity to help you know better our interactions with those whoever need to outside the walls of J&J.

Fintan Walton:

Right, so there are name changes going on, but also as you and I both know there are changes in our industry not just at the pharmaceutical level but also at the biotech level changes in biotech funding and so forth, what is Janssen Pharmaceuticals doing to accommodate that change?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Rob Wills

Vice President

Rob Wills Vice President, Alliance Management, Johnson & Johnson. He is responsible for managing strategic alliances for the Pharmaceutical Group worldwide. This includes the relationships for Velcade, ceftobiprole, rivaroxaban, telaprevir, tapentadol, Yondelis and others. As head of Alliance Management, he oversees a small group of professionals who play an active role in the negotiations of alliances (structure, governance, dispute resolution, communication), in leading the integration post-signing and in managing the overall alliances. Prior to moving into this role in late 2001, Dr Wills spent 22 years in pharmaceutical drug development including, 12 of which have been at Johnson & Johnson. In his previous role as Sr Vice President Global Development, he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr Wills began his career at Hoffmann-La Roche where he spent 10 years in several roles of scientific responsibility. Much of Dr Wills' accomplishments are related to his R&D career, which included the successful development of over 30 NDA's, PLA's, MAA's in multiple therapeutic areas. He has authored over 40 peer reviewed research articles, 5 book chapters, and 50 professional presentations or abstracts in the area of pharmacokinetics. Dr Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Janssen Pharmaceuticals LLC

Janssen Pharmaceuticals LLC a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer's disease, epilepsy, migraine prevention and treatment), pain management, and women's health . Headquartered in Titusville, New Jersey, Janssen is named after Dr. Paul Janssen, a leading Belgian researcher, pharmacologist, and general practitioner. Dr. Janssen led a group of researchers to discover a medicine that helped change the way mental health patients were treated. His company, Janssen Pharmaceutica, joined the Johnson & Johnson family of companies in 1961.